161 related articles for article (PubMed ID: 23138882)
1. Midterm outcome of risedronate therapy for patients with Paget's disease of bone in the central part of Japan.
Nishida Y; Yamada Y; Tsukushi S; Sugiura H; Urakawa H; Ishiguro N
Clin Rheumatol; 2013 Feb; 32(2):241-5. PubMed ID: 23138882
[TBL] [Abstract][Full Text] [Related]
2. Efficacy, tolerability, and safety of risedronate in Japanese patients with Paget's disease of bone.
Yoh K; Takata S; Yoshimura N; Hashimoto J
J Bone Miner Metab; 2010 Jul; 28(4):468-76. PubMed ID: 20179977
[TBL] [Abstract][Full Text] [Related]
3. A randomized, double-blind comparison of risedronate and etidronate in the treatment of Paget's disease of bone. Paget's Risedronate/Etidronate Study Group.
Miller PD; Brown JP; Siris ES; Hoseyni MS; Axelrod DW; Bekker PJ
Am J Med; 1999 May; 106(5):513-20. PubMed ID: 10335722
[TBL] [Abstract][Full Text] [Related]
4. Clinical efficacy of oral risedronate therapy in Japanese patients with Paget's disease of bone.
Ohara M; Imanishi Y; Nagata Y; Ishii A; Kobayashi I; Mori K; Ito M; Miki T; Nishizawa Y; Inaba M
J Bone Miner Metab; 2015 Sep; 33(5):584-90. PubMed ID: 25319558
[TBL] [Abstract][Full Text] [Related]
5. Risedronate: a new oral bisphosphonate.
Umland EM; Boyce EG
Clin Ther; 2001 Sep; 23(9):1409-21. PubMed ID: 11589256
[TBL] [Abstract][Full Text] [Related]
6. Paget's disease of bone: reduction of disease activity with oral risedronate.
Hosking DJ; Eusebio RA; Chines AA
Bone; 1998 Jan; 22(1):51-5. PubMed ID: 9437513
[TBL] [Abstract][Full Text] [Related]
7. [Therapeutic effects of risedronate on Paget's disease of bone].
Takata S
Clin Calcium; 2006 Sep; 16(9):1508-12. PubMed ID: 16951476
[TBL] [Abstract][Full Text] [Related]
8. Risedronate, a highly effective, short-term oral treatment for Paget's disease: a dose-response study.
Brown JP; Hosking DJ; Ste-Marie L; Johnston CC; Reginster J; Ryan WG; Johnson TD; Bekker PJ
Calcif Tissue Int; 1999 Feb; 64(2):93-9. PubMed ID: 9914313
[TBL] [Abstract][Full Text] [Related]
9. Long-term control of bone turnover in Paget's disease with zoledronic acid and risedronate.
Hosking D; Lyles K; Brown JP; Fraser WD; Miller P; Curiel MD; Devogelaer JP; Hooper M; Su G; Zelenakas K; Pak J; Fashola T; Saidi Y; Eriksen EF; Reid IR
J Bone Miner Res; 2007 Jan; 22(1):142-8. PubMed ID: 17032148
[TBL] [Abstract][Full Text] [Related]
10. Safety and effectiveness of risedronate in Paget's disease of bone: postmarketing surveillance study in Japan.
Hashimoto J; Arai Y; Kurosu S; Ikezaki T
J Bone Miner Metab; 2024 Jan; 42(1):122-133. PubMed ID: 38197974
[TBL] [Abstract][Full Text] [Related]
11. Risedronate and pamidronate treatment in the clinical management of patients with severe Paget's disease of bone and acquired resistance to bisphosphonates.
Rendina D; Mossetti G; Viceconti R; Sorrentino M; Nunziata V
Calcif Tissue Int; 2004 Sep; 75(3):189-96. PubMed ID: 15148558
[TBL] [Abstract][Full Text] [Related]
12. Risedronate in the treatment of Paget's disease of bone: an open label, multicenter study.
Siris ES; Chines AA; Altman RD; Brown JP; Johnston CC; Lang R; McClung MR; Mallette LE; Miller PD; Ryan WG; Singer FR; Tucci JR; Eusebio RA; Bekker PJ
J Bone Miner Res; 1998 Jun; 13(6):1032-8. PubMed ID: 9626635
[TBL] [Abstract][Full Text] [Related]
13. Severe hypocalcemia following bisphosphonate treatment in a patient with Paget's disease of bone.
Whitson HE; Lobaugh B; Lyles KW
Bone; 2006 Oct; 39(4):954-8. PubMed ID: 16769264
[TBL] [Abstract][Full Text] [Related]
14. Long-term control of Paget's disease of bone with low-dose, once-weekly, oral bisphosphonate preparations, in a "real world" setting.
Liel Y; Abu Tailakh M
Endocrine; 2019 Mar; 63(3):651-656. PubMed ID: 30406885
[TBL] [Abstract][Full Text] [Related]
15. Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease.
Reid IR; Miller P; Lyles K; Fraser W; Brown JP; Saidi Y; Mesenbrink P; Su G; Pak J; Zelenakas K; Luchi M; Richardson P; Hosking D
N Engl J Med; 2005 Sep; 353(9):898-908. PubMed ID: 16135834
[TBL] [Abstract][Full Text] [Related]
16. Treatment with tiludronate has a similar effect to risedronate on Paget's disease activity assessed by bone markers and bone scintigraphy.
Peris P; Alvarez L; Vidal S; Martínez MA; Monegal A; Guañabens N
Clin Exp Rheumatol; 2007; 25(2):206-10. PubMed ID: 17543143
[TBL] [Abstract][Full Text] [Related]
17. Risedronate: a review of its pharmacological properties and clinical use in resorptive bone disease.
Dunn CJ; Goa KL
Drugs; 2001; 61(5):685-712. PubMed ID: 11368289
[TBL] [Abstract][Full Text] [Related]
18. Improvement of pagetic bone lesions with risedronate treatment: a radiologic study.
Brown JP; Chines AA; Myers WR; Eusebio RA; Ritter-Hrncirik C; Hayes CW
Bone; 2000 Mar; 26(3):263-7. PubMed ID: 10709999
[TBL] [Abstract][Full Text] [Related]
19. Effects of risedronate on bone turnover markers in osteoporotic postmenopausal women: comparison of two protocols of treatment.
Bahlous A; Bouzid K; Sahli H; Sallami S; Abdelmoula J
Tunis Med; 2009 Jun; 87(6):380-1. PubMed ID: 19927782
[TBL] [Abstract][Full Text] [Related]
20. The use of risedronate in Paget's disease.
Miller PD
Bone; 1999 May; 24(5 Suppl):91S-92S. PubMed ID: 10321937
[No Abstract] [Full Text] [Related]
[Next] [New Search]
